There is a moment in every startup's life when the founding team realises something uncomfortable: the skills that got you here will not get you there. Building a product and winning early customers requires creativity, speed, and risk tolerance. Scaling from £10M to £50M ARR requires something different entirely — operational discipline, governance frameworks, and financial rigour that would have felt premature eighteen months ago but are now essential to survival.
NovaTech has reached this inflection point. With £22M ARR, 82% gross margins, and a team of 120 people, the company is no longer a startup. It is a scale-up, and the operational challenges it faces are fundamentally different from anything the founders have navigated before.
The growth stage is where startups become real companies. The founders who succeed are those who embrace operational excellence not as a constraint on innovation, but as the foundation that makes sustained innovation possible. Every process you build, every governance framework you implement, every financial discipline you adopt is an intangible asset that compounds your company's value.
Operating Leverage: How SaaS Companies Become Profitable
Operating leverage is the mechanism by which SaaS companies transition from loss-making growth businesses to highly profitable enterprises. It works because software has near-zero marginal cost — once you have built the platform, each additional customer adds revenue but very little incremental cost.
The mathematics are straightforward but powerful. As revenue grows, fixed costs (R&D, G&A, office space) are spread across a larger base. Variable costs (hosting, customer success, payment processing) grow, but more slowly than revenue. The gap between revenue growth and cost growth is operating leverage, and it widens with every percentage point of scale.
NovaTech's current operating margin of -8% might appear concerning in isolation, but the trajectory tells a different story. Twelve months ago, the operating margin was -24%. The improvement came not from cutting costs but from revenue growing faster than expenses. At the current 60% year-on-year growth rate and 72% contribution margins, NovaTech's financial model projects profitability at approximately £35M ARR.
NovaTech's engineering team costs £6.2M annually — roughly 28% of ARR. At £22M ARR, this feels expensive. At £50M ARR (projected within 24 months), the same team — even with modest salary inflation and a few key hires — would cost approximately £7.8M, or just 15.6% of ARR. That 12.4 percentage point improvement drops straight to the operating line. This is operating leverage in action.
The Board's Great Debate: Growth vs Profitability
Every growth-stage company faces a strategic fork in the road. NovaTech's board spent three meetings debating it: should the company accelerate growth by investing the remaining Series B capital aggressively, or should it optimise for profitability to reduce dependence on future fundraising?
Accelerate Growth
- Push for 80%+ YoY growth
- Expand sales team from 20 to 35 reps
- Enter US market 6 months earlier
- Requires Series C within 18 months
- Higher valuation but more dilution
Optimise for Profitability
- Maintain 60% YoY growth
- Reach breakeven at £35M ARR
- Optional Series C from position of strength
- Lower dilution, more founder control
- Risk: competitors may outpace in market capture
The answer depends on market dynamics. In NovaTech's case, the AI supply chain analytics market was consolidating rapidly. Two competitors had also raised significant rounds. The board chose a middle path: maintain 60% growth while driving towards profitability, but reserve the option to accelerate if competitive dynamics demanded it. This required operational excellence — doing more with less, rather than simply spending more.
R&D Capitalisation: When Development Becomes an Asset
One of the most significant financial decisions at the growth stage is whether to capitalise research and development costs. Under IAS 38 — the international accounting standard governing intangible assets — certain development expenditure can be recognised as an asset on the balance sheet rather than expensed through the profit and loss account.